Roche’s Phase III trials of vamikibart for uveitic macular edema show promising results, with improvements in vision and reductions in retinal swelling. The MEERKAT trial found vamikibart to be superior to sham, while the SANDCAT trial did not reach statistical significance. Safety data showed vamikibart was well tolerated, with few ocular adverse events reported. Common side effects included conjunctival hemorrhage and elevated intraocular pressure. Further analysis is ongoing to understand the variability in outcomes. No cases of retinal occlusive vasculitis were reported. More health news can be found at rttnews.com.

Read more at Nasdaq.: Roche’s Vamikibart Shows Promising Efficacy In Uveitic Macular Edema Across Phase III Trials